ClearPoint Neuro CEO Joseph Burnett disposes of common shares worth $1.1 million

ClearPoint Neuro CEO Joseph Burnett sold 60,000 shares at $17.79 on June 17, 2026, after exercising options at $2.50. This transaction reduced his direct stake to 116,842 shares. Additionally, a trust linked to Burnett sold 1,843 shares at $17.94, leaving 191,388 indirect shares. Burnett retains 270,000 stock options.

ClearPoint Neuro CEO and President Joseph Burnett exercised stock options for 60,000 shares at USD 2.5 on June 17, 2026. * He sold 60,000 shares at USD 17.79, cutting his directly held stake to 116,842 shares. * A trust linked to Burnett sold 1,843 shares at USD 17.94, leaving 191,388 shares held indirectly. * Burnett reported 270,000 stock options remaining after the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-277503), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

ClearPoint Neuro CEO and President Joseph Burnett exercised stock options for 60,000 shares at USD 2.5 on June 17, 2026. * He sold 60,000 shares at USD 17.79, cutting his directly held stake to 116,842 shares. * A trust linked to Burnett sold 1,843 shares at USD 17.94, leaving 191,388 shares held indirectly. * Burnett reported 270,000 stock options remaining after the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-277503), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here